Previous studies have shown that high affinity nicotinic receptor numbers increase in the brains of human subjects who smoke (Benwell et al. 1988; Breese et al. 1997a; Court et al. 1998) . This increase was shown to be dosedependent, based on the number of cigarettes smoked at death, and was reversible, with binding levels returning to control values in subjects who had quit smoking for at least two months prior to death (Breese et al. 1997a) . The up-regulation of receptor numbers does not appear to be under transcriptional regulation (Marks et al. 1992) . Rather, the increases may be related to changes in receptor turnover based on receptor desensitization, subunit composition, secondary structural changes in the receptor, or to modification of the receptor by protein kinases (Peng et al.
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In spite of the high degree of nicotine self-administration in schizophrenics (Lohr and Flynn 1992; Ziedonis et al. 1994; de Leon et al. 1995) , few studies have examined the effect of smoking or neuroleptic treatment on nicotinic receptor regulation in this disease (Dalack et al. 1998) . It has been suggested that nicotine self-administration in schizophrenics may control a neuronal deficit. In this regard, it has been shown that abnormal electro-N EUROPSYCHOPHARMACOLOGY 2000 -VOL . 23 , NO . 4 physiological and eye-tracking deficits can be normalized by cigarette smoking or nicotine administration (Adler et al. 1992 (Adler et al. , 1993 Olincy et al. 1998) . Smoking may also alleviate neuroleptic-induced extrapyramidal side effects (Decina et al. 1990; Goff et al. 1992; Sandyk 1993) . Nicotine use increases haloperidol metabolism (Jann et al. 1986; Miller et al. 1990) , requiring patients that smoke to take higher doses than non-smoking schizophrenics, often further increasing their smoking behavior (McEvoy et al. 1995) . Interestingly, clozapine, which does not induce the motor dysfunctions seen with typical neuroleptics, reduces smoking behavior (George et al. 1995) and normalizes the electrophysiological deficit in schizophrenics .
Earlier studies from this laboratory have shown that schizophrenics have a reduced number of ␣ -bungarotoxin ( ␣ -BTX) binding sites in hippocampus, indicative of a reduction in the ␣ -7 neuronal nicotinic receptor (Freedman et al. 1995; Leonard et al. 1996 Leonard et al. , 1998a Adler et al. 1998) . Involvement of the ␣ -7 receptor in schizophrenia is further supported by genetic linkage to the region containing the ␣ -7 nicotinic receptor Leonard et al. 1998b; Kaufmann et al. 1998; Riley et al. 2000) and by animal studies showing that antagonists of the ␣ -7 nicotinic receptor induce sensory gating deficits similar to those seen in schizophrenia (Luntz-Leybman et al. 1992; Stevens et al. 1996 Stevens et al. , 1998 . In the present study, the effect of smoking history on the regulation of the high affinity nicotinic receptor ligands, [ ]-methyllycaconitine (MLA), was examined in several brain regions from normal control and schizophrenic subjects. An examination of the possible interaction of nicotine and neuroleptic treatment on nicotinic receptor regulation was performed in rats chronically treated with haloperidol, nicotine and the combination of these drugs.
MATERIALS AND METHODS

Human Postmortem Brain Collection and Storage
Human brains were collected at autopsy following family donation. Hospital and autopsy records were reviewed, and family members and physicians interviewed to detail the age, sex, race, cause of death, mental illnesses, as well as cigarette, alcohol, and drug use. Subject parameters are shown in Table 1 . After the brain was weighed and examined for gross pathology, it was divided sagitally and one hemisphere was preserved in formalin for neuropathological analysis. The other hemisphere was sliced coronally into 1 cm slices, from which regions of interest were dissected in 1 gram blocks, frozen in dry ice snow, and packaged for storage at Ϫ 75 Њ C (Leonard et al. 1993 ).
In these studies, subjects with schizophrenia were compared to non-psychotic control patients. Patients with schizotypal and bipolar disorders were excluded from analysis. Schizophrenic subjects with verifiable medication histories were on typical antipsychotic medications (haloperidol and phenothiazine derivatives) except for subject SL163, who had been on clozapine for more than three years before death (see Table 1 ). Differing sample numbers used for binding studies in the various brain regions were a result of tissue availability.
Tissue Homogenate Preparation
Dissected regions of human postmortem hippocampus, cortex (Brodmann area 8/9), caudate, and thalamus were weighed and homogenized in 10 volumes of ice cold Krebs-Ringer's HEPES buffer (118 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl 2 , 1.2 mM MgSO 4 , 20 mM HEPES, pH 7.5) in a Potter-Elvehjem homogenizer using a motor driven Teflon pestle (Breese et al. 1997a) .
Three centrifugation steps (30,000g) following homogenization or resuspension of pellet in 0.1 ϫ KrebsRinger's HEPES were included to provide thorough dissociation and washing of membranes. Following the final wash, pellets were resuspended in 0.1 ϫ KrebsRinger's HEPES buffer (1 ml/100 mg original wet weight), aliquoted, and assayed for protein content (BCA assay; Pierce, Rockford, IL). Membranes were stored at Ϫ 75 Њ C until analyzed for [ Although nicotine is the traditional ligand used for high affinity nicotinic receptor binding studies (Marks and Collins 1982; Breese et al. 1997a) , we also used [ 3 H]-epibatidine, which had a higher affinity and lower non-specific binding similar to that seen in rat (Houghtling et al. 1995 ). H]-nicotine, specific activity 82 Ci/mmol; Amersham Corp., Arlington Heights, IL) was repurified in order to reduce nonspecific binding of the labeled ligand (Romm et al. 1990) . [ 3 H]-Nicotine binding was measured at 4 Њ C, as previously described in hippocampal, thalamic, and cortical tissue (Breese et al. 1997a) . Briefly, incubations were conducted at a volume of 100 l in 96-well polystyrene culture dishes. Samples containing 100-200 g of protein were incubated at 4 Њ C for 2 hrs in Krebs-Ringers HEPES containing 200 mM Tris. The binding reaction was terminated by filtration in an Inotech cell harvester apparatus (top filter: GB100 (Micro Filtration Systems, Dublin, CA); bottom filter: Type A/E (Gelman Sciences, Ann Arbor, Ml)), and filters counted on a Beckman LS3000 Liquid Scintillation Spectrometer (counting efficiency, Ϸ 52%).
L-[
H]-Nicotine Binding
Non-specific binding was established by inclusion of 10 M unlabeled nicotine in the incubation. (Davies et al. 1999) . Total binding was done in 10 nM [ 3 H]-MLA and non-specific binding was defined in the presence of 1 mM nicotine. Samples were incubated 2 hrs at room temperature, then filtered as described.
Chronic Nicotine and Haloperidol Treatment in Rats
A rat model was used to examine nicotinic receptor regulation in a controlled experimental paradigm of chronic neuroleptic and nicotine exposure. Animals were housed two per cage on a 12:12 light:dark cycle (lights on at 0700 hrs) and allowed access to food and water ad libitum. Four groups of rats ( n ϭ 10 per group) were injected twice daily (0800 and 1800 hrs) with saline, 1.25 mg/kg nicotine (total dose 2.5 mg/kg/day), 1 mg/kg haloperidol (total dose 2 mg/kg/day), or the combination of nicotine and haloperidol for six weeks. Eight hours after the last treatment, animals were sacrificed by CO 2 inhalation, the brains rapidly removed, and the cortical mantel dissected and stored at Ϫ 75 Њ C until tissue homogenization and receptor binding assays were performed, as described above.
Data Analysis
Specific binding (fmoles/mg protein) was calculated for each ligand. In studies using human postmortem brain tissue, correlational analyses were performed with age, sex, PMI, storage time, drug and alcohol histories in order to examine the possible role of these variables on the results. All data were analyzed using ANOVA by comparing the nicotine or epibatidine binding levels in schizophrenic and control subjects in adult nonsmokers, smokers at the time of death, and smokers who had quit at least two months prior to death. Appropriate specific contrasts were performed in order to identify the sources of variance.
Rat data was analyzed by ANOVA, followed by appropriate specific contrast (Crunch statistical software, Oakland, CA) (Keppel 1991) . A correlational analysis was also performed using smoking history, defined as the number of packs smoked per day at death, and specific ligand binding (Breese et al. 1997a ). The saturation analysis was performed with Prizm (GraphPad Software Inc., San Diego, CA), using a non-linear regression analysis.
RESULTS
Postmortem Brain Tissue Samples
Neuropathological analysis revealed that tissue samples used in this study were free of neuropathological disorders. There was no statistical difference based on smoking histories between control and schizophrenic subjects (1.57 Ϯ 0.02 vs 1.9 Ϯ 0.4 packs per day, p ϭ .17). There were no statistical differences or interactions for age of the subjects at death (average age, 55.4 Ϯ 1.7 years), or tissue storage time (hippocampal and thalamic tissues average storage, 865 Ϯ 57 days; cortex and caudate average storage, 1228 Ϯ 61 days), when compared with either mental illness or smoking history.
While there was a significantly longer postmortem interval (PMI) in schizophrenic subjects (18.32 Ϯ 1.49 vs. 14.87 Ϯ 0.8, p ϭ .03), there were no differences in PMI based on smoking history, nor was there an interaction based on mental illness and smoking history (both p Ͼ .25). Correlational and statistical analyses showed no differences between control subjects and subjects with alcohol use or depression histories; therefore, these subjects were further analyzed as non-psychotic control subjects.
Correlational analyses were performed using various subject and tissue collection parameters with nicotinic receptor binding in order to examine the potential influence of these variables on the data. The results are summarized for [ H-methyllycaconitine binding in cortex. Abbreviations: COD ϭ cause of death (see below for key); PMI ϭ postmortem interval; Drugs: Known medications at time of death. Race: C ϭ Caucasian, B ϭ Black, H ϭ Hispanic, A ϭ Asian, U ϭ Undetermined. COD (cause of death): cdis ϭ chronic disease, adis ϭ acute disease, card ϭ cardiac arrest, suic ϭ suicide, trma ϭ trauma, resp ϭ respiratory disease, renl ϭ renal failure. Drugs: P ϭ history of antipsychotic drug use (* clozapine), D ϭ history of antidepressant drug use, B ϭ history of antipsychotic and antidepressant drug use, N ϭ no drugs in these classes at time of death, L ϭ lithium, U ϭ unverified drug status at time of death. subjects in hippocampus and cortex, and in control subjects in cortex (Figure 1, right) Figure 3 . As originally described in a smaller group of subjects (Breese et al. 1997a) , control smokers had significantly increased mean [ 3 H]-nicotine binding compared to either nonsmokers or smokers who had quit in both hippocampus ( Figure 3 , upper left; n ϭ 42, both p Ͻ .0001) and thalamus ( Figure 3 , upper right; n ϭ 34, p Ͻ .01). This increase in nicotinic receptor levels in the human postmortem brains of smokers was replicated in a larger subject population using cortical tissues (n ϭ 57) (Figure 3 , lower left). In schizophrenic subjects, there was no such relationship between smoking history and [ 3 H]-nicotine receptor binding in any of these tissues. In hippocampus ( Figure 3 , upper left; n ϭ 22; p ϭ .45) and thalamus (Figure 3 , upper right; n ϭ 17; p ϭ .67), there were no differences between schizophrenic nonsmokers, smokers, or smokers who had quit. The cortex (n ϭ 31) was the only region which showed a marginally significant difference in [ When control smokers were compared directly to schizophrenic smokers, schizophrenic smokers had signif- icantly lower nicotinic receptor levels than control smokers in both hippocampus ( Figure 3 , upper left; p Ͻ .05) and cortex ( Figure 3 , lower left; p Ͻ .03), although there was no significant change in thalamus (Figure 3, upper right) .
Since a significant correlation was observed between age and nicotinic receptor levels in both control and schizophrenic subjects in cortex, ANOVA was performed using age as a covariant in order to examine the potential effect of age on the reported results. In both subject groups co-varied for age, the overall results were similar to those described above, indicating that age was not a confounding variable in these analyses. In the caudate nucleus of control subjects ( Figure 3 , lower right; n ϭ 56), [ 3 H]-epibatidine binding was also significantly increased in smokers compared to either nonsmokers or smokers who had quit (both p Ͻ .001). As with nicotine binding, there was also a difference in [ 3 H]-epibatidine binding in cortex between schizophrenic smokers and nonsmokers ( Figure 3 , lower left; p Ͻ .03). In caudate (n ϭ 26), there was no significant difference between schizophrenic nonsmokers, smokers, or smokers who quit ( Figure 3 , lower right; all p Ͼ .50). In both tissues, schizophrenic smokers demonstrated significantly reduced levels of [ 3 H]-epibatidine binding in both the cortex and caudate nucleus of smokers compared to either nonsmokers, or smokers who had quit. In schizophrenic subjects, no such relationship between smoking history and nicotinic receptor levels was observed. In hippocampus, cortex, and caudate there was a significant reduction in nicotinic receptor numbers in schizophrenic smokers compared to control smokers (all p Ͻ .05). The only brain region which showed a difference in nicotinic receptor levels between schizophrenic nonsmokers and smokers was in cortex (both p Ͻ .05; * comparison between nonsmokers and smokers within the control or schizophrenic groups (all p Ͻ .05); # comparison between control smokers and schizophrenic smokers (all p Ͻ .05)).
binding when compared to control smokers (cortex: p Ͻ .03; caudate: p Ͻ .015).
Comparison of [ 3 H]-Nicotine and [
H]-Epibatidine Binding with Smoking History
Since previous studies showed a dose-dependency in nicotinic receptor up-regulation (Breese et al. 1997a (Breese et al. 1997a) . As shown in Figure 4 , nicotinic receptor binding increased in normal control subjects with increasing numbers of packs of cigarettes smoked per day, with positive correlations in hippocampus (r ϭ 0.64, p Ͻ .0001), thalamus (r ϭ 0.46, p Ͻ .02), cortex (r ϭ 0.64 p Ͻ .0001), and caudate (r ϭ 0.38, p Ͻ .02).
In schizophrenic subjects, while there was a positive correlation of nicotinic receptor numbers in hippocampus (r ϭ 0.56, p Ͻ .02) and cortex (r ϭ 0.44, p Ͻ .02) with increasing smoking history, the slope of the regression lines were decreased 40% in hippocampus and 50% in cortex relative to normal smokers (hippocampus: normal slope ϭ 6.58 Ϯ 1.4; schizophrenic slope ϭ 3.99 Ϯ 1.5; cortex (nicotine binding): normal slope ϭ 11.02 Ϯ 2.1; schizophrenic slope ϭ 5.48 Ϯ 2.23). ), the slope of the regression line (dashed line) was decreased to 39.4% of the rate of normal smokers in hippocampus. The slope of the regression line in the cortex was reduced 50.3% and 45.6% for nicotine and epibatidine binding (respectively) in schizophrenics compared to normal smokers. In contrast to the dose dependent increase observed in thalamus and caudate of normal smokers, no correlation was found in schizophrenics between nicotine dose and [
3 H]-nicotine binding for either tissue (thalamus: r ϭ Ϫ 0.12, p ϭ .68; caudate nucleus: r ϭ 0.31, p ϭ .15). The slope of the regression line in the caudate nucleus was reduced 60.2% in schizophrenics compared to control subjects.
Results from [
3 H]-epibatidine binding in the cortex were nearly identical to those found for [ 3 H]-nicotine binding (normal: r ϭ 0.63, p Ͻ .0001, slope ϭ 14.4 Ϯ 2.8; schizophrenic: r ϭ 0.49, p Ͻ .01, slope ϭ 7.84 Ϯ 2.8; 44% reduction in slope of regression line). In thalamus and caudate, nicotinic receptors in schizophrenic subjects were not significantly correlated with smoking history (thalamus: r ϭ Ϫ 0.12, p ϭ .68; caudate: r ϭ 0.31, p ϭ .15). In caudate, the reduction in the slope of the regression line was 60% (normal slope ϭ 4.99 Ϯ 1.9; schizophrenic slope ϭ 1.98 Ϯ 1.34). In thalamus, there appeared to be a general dysregulation of nicotinic receptor upregulation in schizophrenics (normal slope ϭ 8.5Ϯ 3.2; schizophrenic slope ϭ Ϫ1.72 Ϯ 4.0).
Also as shown in Figure 4 , the intercepts for hippocampus, caudate, and cortex were nearly identical for both control and schizophrenic subjects. This, in addition to the fact that there were no differences between control and schizophrenic nonsmokers (all p Ͼ.1), indicated that normal control and schizophrenic subjects have approximately the same basal levels of receptors in these brain regions. This was not the case in the thalamus, in which schizophrenic nonsmokers at death had marginally higher basal levels than control subjects (p Ͻ .05).
Scatchard Analysis
Scatchard analyses were performed in cortical tissues using both [ cifically examined in the other tissues used in this study, previous results in mice (Marks et al. 1985) and human postmortem brain (Benwell et al. 1988; Breese et al. 1997a ) have shown that the receptor affinity for [ 3 H]-nicotine binding was similar throughout the brain, and was not changed as a result of nicotine treatment or smoking history. (Freedman et al. 1995; Breese et al. 1997b ). While schizophrenic subjects had reduced average levels of [ 
Effect of Chronic Neuroleptic and Nicotine Treatment on [
H]-Epibatidine Receptor Binding in Rats
The effect of chronic nicotine, haloperidol, and co-treatment on [ 
DISCUSSION
Previous results have shown that the high affinity neuronal nicotinic receptors were up regulated in hippocampus and thalamus of subjects that smoke, compared to nonsmokers (Breese et al. 1997a ). This increase was both dose-dependent and reversible. The present results extend these findings to cortex, a region sensitive to the regulatory effects of chronic nicotine treatment in rodents (Marks et al. 1985) , and caudate, a region with a high density of dopaminergic terminals. In subjects with no history of mental illness, a significant increase in nicotinic receptor binding in these brain regions was seen in smokers compared to either nonsmokers or smokers who had quit. The increases were also correlated with packs smoked per day, further demonstrating the dose-dependency of nicotinic receptor up-regulation in human brain. Nicotinic receptor binding in smokers who had quit was comparable to nonsmokers, showing the reversibility of nicotinic receptor up-regulation in these brain regions when tobacco use is discontinued (Breese et al. 1997a ). Scatchard analysis further indicated that these changes were related to changes in receptor number since the binding affinity of the neuronal nicotinic receptors was not changed as a result of smoking history (Breese et al. 1997a) .
In the present study, schizophrenic subjects did not demonstrate the same regulatory responses for the high affinity neuronal nicotinic receptors as seen in control smokers. Schizophrenics who smoked demonstrated an overall reduction in the normal up-regulation of high affinity neuronal nicotinic receptors in most brain regions examined. While basal binding levels were not different between control and schizophrenic subjects, the reduction in high affinity nicotinic receptor binding in schizophrenic smokers was observed in group means, as well as in the regression analysis. The slope of the regression line, based on nicotinic receptor binding and number of cigarettes smoked per day, was reduced up to 60% in schizophrenic subjects, indicating a failure to up-regulate the high affinity neuronal nico- tinic receptors at any given smoking level compared to controls. Scatchard analyses suggested that the changes seen in nicotinic receptor levels were due to changes in total receptor numbers (B max ) and not to a change in receptor affinity (K d ).
Since schizophrenics are primarily treated with drugs that block dopaminergic neurotransmission, it was of interest to examine brain regions with dopaminergic innervation, namely striatum and cortex. In this study, caudate was examined as a representative region of striatum for measuring changes in high affinity neuronal nicotinic receptor binding in control smokers and schizophrenic subjects. Caudate, as well as cortex, showed a reduced level of nicotinic receptor upregulation in schizophrenics, compared to control subjects, suggesting that cholinergic modulation of dopaminergic neurotransmission might be affected in schizophrenia (Grenhoff and Svensson 1988; Rapier et al. 1990; Rowell 1995; Blaha et al. 1996; Pidoplichko et al. 1997) . It is also interesting to note that schizophrenics demonstrated age related changes in neuronal nicotinic receptor numbers in both cortex and hippocampus, whereas control subjects demonstrated changes only in the cortex.
Previous results suggest that schizophrenics may have a loss of cognitive function (Hyde et al. 1994; Goldstein et al. 1998; Heinrichs and Zakzanis 1998) , and an accelerated loss of nicotinic cholinergic receptors with age would be consistent with this finding.
The failure of up-regulation of the nicotinic receptors in smoking schizophrenics was not expected. Approximately 80% of schizophrenics smoke, compared with 20-30% of the general population (Lohr and Flynn 1992; Ziedonis et al. 1994; de Leon et al. 1995) , and it has been shown that schizophrenics extract a greater amount of nicotine from each cigarette smoked compared to control subjects . While a number of factors should be considered as possible mechanisms for the aberrant regulation of nicotinic receptor levels in schizophrenic brain, the use of neuroleptic medication was a primary concern, as the postmortem tissue used in the present study was primarily from subjects receiving typical neuroleptic medication in life. Therefore, haloperidol was used to assess the effect of chronic neuroleptic and nicotine treatment on nicotinic receptor levels in rat cortex.
Rats treated with the typical neuroleptic haloperidol had the same level of [ 3 H]-nicotine binding as saline control animals in cortex, indicating that haloperidol alone had no effect on nicotinic receptor expression. Combination treatment with haloperidol and nicotine induced similar increases in nicotine binding as nicotine treatment alone. Further studies have indicated similar results in other rat brain regions . Interestingly, schizophrenics failed to show any upregulation in thalamus from baseline levels. In thalamus, upregulation in response to nicotine can be reduced and variable, particularly at low doses of nicotine (Marks et al. 1992; Flores et al. 1997; Ulrich et al. 1997; Breese et al. 1997a) , indicating that thalamus may be refractory to nicotinic receptor upregulation. While neuroleptic treatment may have affected receptor upregulation of the high affinity receptors in thalamus, the lack of correlation may be related to the expression of other receptor subtypes (Marks et al. 1992 ) that do not demonstrate the same degree of receptor upregulation to chronic nicotine treatment as the ␣4␤2 subtype (Fenster et al. 1999) .
Although the abnormal regulation of the high affinity neuronal nicotinic receptors in schizophrenia appears to be generally unrelated to chronic neuroleptic treatment, the attenuation of nicotine-induced upregulation in thalamus does suggest possible interactions with other neurotransmitter systems. In addition to the effects of neuroleptic treatment, a recent report suggested that smoking might increase the activity of specific P450 enzymes, leading to increased metabolism of nicotine (Nakajima et al. 1996) . However, the experiments reported here do not support such a hypothesis, since haloperidol did not change the up-regulation of receptor levels in rat cortex following chronic nicotine exposure. The haloperidol experiment does not rule out changes due to an interaction of age and long-term neuroleptic treatment, nor effects with atypical neuroleptics such as clozapine.
Previous attempts to measure differences in ␣-7 expression in human postmortem brain using [
125 I]-␣-bungarotoxin homogenate binding have thus far been unsuccessful, primarily due to the extremely low level of expression and high levels of background binding seen with the use of this ligand. In the present study [ 3 H]-MLA, a potent and selective antagonist at the ␣-BTX binding site (Ward et al. 1990; Davies et al. 1999) , was used to measure the ␣-7 receptor levels in membranes from hippocampus and cortex. A small reduction in [ 3 H]-MLA binding was seen in schizophrenic subjects in both brain regions, but these differences were not statistically significant. Previous results have shown a reduction in schizophrenic postmortem hippocampus using [ 125 I]-␣-BTX receptor autoradiography (Freedman et al. 1995) . Due to the extremely low levels and small numbers of ␣-7 expressing cells in these regions of human brain (Breese et al. 1997b) , receptor autoradiography may be a more appropriate method to measure this receptor subtype.
It has been shown in rodents that increases in nicotinic receptor number following chronic nicotine treatment were not due to increases in mRNA levels (Marks et al. 1992) . Whether this is true in human brain is currently under investigation. Results from rodent and cell culture experiments suggest that nicotine-induced increases in nicotinic receptor levels result from a modification to the receptor protein as a result of nicotine binding. It has been hypothesized that increases in nicotinic receptor number and the decreased rate of receptor turnover (Peng et al. 1994 ) are related to the conformational state of the nicotinic receptor and subsequent receptor desensitization (Vibat et al. 1995; Baenziger and Chew 1997) . A recent report further suggests that receptor desensitization is required for receptor upregulation, particularly the ␣4␤2 receptor subtype (Fenster et al. 1999) .
To fully explain the present results in schizophrenics, the basis of the paradoxical increase in the neuronal nicotinic receptors in normal human smokers must be known. While it could be hypothesized that the nicotinic receptors are not desensitized in schizophrenics and therefore fail to upregulate, data showing a transient effect of nicotine on the normalization of the abnormal auditory gating response in schizophrenics do not support this hypothesis (Adler et al. 1992 (Adler et al. , 1993 . Nevertheless, schizophrenics could have an abnormality in any of several potential mechanisms that change the desensitization state of the receptor and receptor turnover, as well as activation and ion flux through the receptor.
Whatever the mechanism for the reduced levels of both high and low affinity nicotinic receptors in schizophrenics, the resultant reduced nicotinic cholinergic modulation may induce several secondary effects. There is strong evidence that a large component of nicotinic receptor function involves presynaptic receptor activation (Sershen et al. 1995; Wonnacott 1997; MacDermott et al. 1999) , and as such would be expected to play an important role as a modulator of numerous neurotransmitter systems. The nicotine-stimulated release of multiple types of neurotransmitters is well-documented (Grady et al. 1994; Rowell 1995; Summers and Giacobini 1995; Bertolino et al. 1997; Liang and Vizi 1997; Wonnacott 1997; Summers et al. 1997; Takahashi et al. 1998 ). In addition, nicotinic autoreceptors are thought to function at motor-nerve terminals (Bowman et al. 1988; Tian et al. 1994 ), where they regulate acetylcholine release. This may occur in the brain as well (Rowell and Winkler 1984; Araujo et al. 1988; Wilkie et al. 1996; Summers et al. 1997; Wonnacott 1997) .
Presynaptic receptors in brain also appear to regulate the release of GABA (Yang et al. 1996; Alkondon et al. 1997; Wonnacott 1997) . A possible regulatory relationship between different nicotinic receptor classes involving inhibition of GABA release in hippocampus has been suggested (Alkondon et al. 1997; Albuquerque et al. 1998) . It is interesting to speculate that the decreases in both low and high affinity nicotinic receptor binding seen in schizophrenia might reflect altered receptor subunit ratios in brain, resulting in aberrant inhibitory modulation.
Considering the widespread localization of the neuronal nicotinic receptors and their potential role in modulating numerous neurotransmitter systems in both the brain and periphery, characterization of the nicotinic receptor gene family in schizophrenia and its relationship to the inhibitory deficits and pharmacological medications used in this disease may further the investigation of synaptic modulation in human brain and provide new avenues for treatment.
